{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:41:51Z","timestamp":1790962911349,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"am","delay-in-days":441,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02941"],"award-info":[{"award-number":["21H02941"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jdermsci.2021.11.009","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T11:25:45Z","timestamp":1637839545000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets"],"prefix":"10.1016","volume":"105","author":[{"given":"Masashi","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2021.11.009_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/jid.2014.46","article-title":"CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort","volume":"134","author":"Sugiura","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib3","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1111\/bjd.15442","article-title":"Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation","volume":"177","author":"Takeichi","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking","volume":"94","author":"Setta-Kaffetzi","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ajhg.2020.07.001","article-title":"Myeloperoxidase modulates inflammation in generalized pustular psoriasis and additional rare pustular skin diseases","volume":"107","author":"Haskamp","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jid.2019.11.024","article-title":"Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis","volume":"140","author":"Frey","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jaci.2017.05.019","article-title":"Autoinflammatory keratinization diseases","volume":"140","author":"Akiyama","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jdermsci.2018.01.012","article-title":"Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin","volume":"90","author":"Akiyama","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib9","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1038\/jid.2014.177","article-title":"IL36RN mutations underlie impetigo herpetiformis","volume":"134","author":"Sugiura","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/1346-8138.15788","article-title":"Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases","volume":"48","author":"Yoshikawa","year":"2021","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism","volume":"98","author":"Murakami","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fimmu.2020.00280","article-title":"Autoinflammatory keratinization diseases (AiKDs): Expansion of disorders to be included","volume":"11","author":"Akiyama","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjd.15867","article-title":"The genetic basis for most patients with pustular skin disease remains elusive","volume":"178","author":"M\u00f6ssner","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib17","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdermsci.2016.10.009","article-title":"A newly revealed IL36RN mutation in sibling cases complements our IL36RN mutation statistics for generalized pustular psoriasis","volume":"85","author":"Takeichi","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaci.2018.11.009","article-title":"Early-onset generalized pustular psoriasis is representative of autoinflammatory keratinization diseases","volume":"143","author":"Akiyama","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/1346-8138.13429","article-title":"Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab","volume":"43","author":"Adachi","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14","volume":"90","author":"Jordan","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajhg.2012.03.013","article-title":"Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis","volume":"90","author":"Jordan","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ajhg.2012.05.010","article-title":"Familial pityriasis rubra pilaris is caused by mutations in CARD14","volume":"91","author":"Fuchs-Telem","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2016.3601","article-title":"Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations","volume":"153","author":"Takeichi","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib26","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production","volume":"136","author":"Mahil","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajhg.2020.06.020","article-title":"Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease.","volume":"107","author":"Vergnano","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib28","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.jid.2021.01.017","article-title":"Genetic analysis of mpo variants in four psoriasis subtypes in patients from Germany.","volume":"141","author":"Haskamp","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40257-019-00492-0","article-title":"Generalized pustular psoriasis: Clinical management and update on autoinflammatory aspects","volume":"21","author":"Takeichi","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/ijd.14671","article-title":"Biological therapy for pustular psoriasis: a systematic review","volume":"59","author":"Falto-Aizpurua","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/1346-8138.14471","article-title":"Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders","volume":"45","author":"Kanekura","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jaad.2012.09.037","article-title":"Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis","volume":"68","author":"Ikeda","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib33","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/jdv.12383","article-title":"Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis","volume":"28","author":"Sugiura","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/1346-8138.15569","article-title":"Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis","volume":"47","author":"Mizutani","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib35","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/1346-8138.15241","article-title":"Impetigo herpetiformis with a CARD14 Thr79Ile variant successfully treated with granulocyte and monocyte adsorption apheresis","volume":"47","author":"Fujii","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib36","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/1346-8138.14191","article-title":"Granulocyte and monocyte adsorption apheresis for palmoplantar pustulosiswith extra-palmoplantar lesions and pustulotic arthro-osteitis","volume":"45","author":"Arimura","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib37","doi-asserted-by":"crossref","unstructured":"S. Cro, V.R. Cornelius, A.E. Pink, R. Wilson, A. Pushpa-Rajah, P. Patel, et al., Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two staged, adaptive placebo controlled trial (APRICOT). Br. J. Dermatol. (in press) 2021 Aug 19; Online ahead of print.","DOI":"10.1111\/bjd.20944"},{"key":"10.1016\/j.jdermsci.2021.11.009_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab.","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful response in a case of severe pustular psoriasis after interleukin-1b inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s13555-018-0269-7","article-title":"Scoping review on use of drugs targeting interleukin 1 pathway in DIRA and DITRA","volume":"8","author":"G\u00f3mez-Garc\u00eda","year":"2018","journal-title":"Dermatol. Ther. (Heidelb)."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib41","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 activity promotes clonal CD4+ T-cell responses with IL-17A production in generalized pustular psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"411","key":"10.1016\/j.jdermsci.2021.11.009_bib42","doi-asserted-by":"crossref","first-page":"eaan2514","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043666","article-title":"Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.","volume":"11","author":"Choon","year":"2021","journal-title":"BMJ Open."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol. Ther. (Heidelb)."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","article-title":"Palmoplantar pustulosis: Recent advances in etiopathogenesis and emerging treatments","volume":"21","author":"Misiak-Galazka","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib47","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.3390\/ijms22094344","article-title":"Exploring the role of IL-36 cytokines as a new target in psoriatic disease","volume":"22","author":"Iznardo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib48","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36\u03b3 antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4049\/jimmunol.181.1.669","article-title":"IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis","volume":"181","author":"Skov","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2021.11.009_bib50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.1801519","article-title":"Efficacy of chemokine receptor inhibition in treating IL-36\u03b1-induced psoriasiform inflammation","volume":"202","author":"Campbell","year":"2019","journal-title":"J. Immunol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121002942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121002942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T10:54:17Z","timestamp":1755946457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181121002942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0923181121002942"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.11.009","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}